LAVAL, Quebec – (BUSINESS WIRE) – Altasciences announced today that it has acquired WCCT Global, Inc., an early-stage clinical research organization (CRO) based in Southern California on the west coast of the United States. This acquisition will complement Altasciences’ current clinical operations in Montreal, Canada and Kansas City, USA, and will be located in close proximity to the Washington State preclinical facility.
“This acquisition expands Altasciences’ presence by providing Phase I and II clinical pharmacology services on the West Coast and adds 180 beds to our current 400 bed offering. In addition, we can expand our capabilities through expertise in ethnobridging and other areas of specialty for difficult-to-recruit study populations, ”added Steve Mason, Co-Chief Operating Officer, Altasciences.
The transaction closed on February 12th.
“This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early drug development solution to address the ever-changing outsourcing challenges of biopharmaceutical companies around the world. We look forward to working side by side with our new team of clinical experts in California, a team that shares our values of excellence, quality and customer focus, ”said Chris Perkin, CEO of Altasciences.
Founded in 1998, WCCT Global has conducted over 600 Phase I studies – an area it specializes in – out of over 1,000 Phase I-IV studies the company has conducted to date.
“Joining the Altasciences team will enhance our offering and enable us to continue to deliver high quality research data to our global biopharmaceutical customers,” said Gregory Hanson, Executive Chairman of WCCT Global.
Altasciences is a mid-sized CRO / CDMO that provides pharmaceutical and biotechnology companies with a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing and analysis services. Altasciences has worked with sponsors for over 25 years to help make better, faster, and wider decisions about early drug development. Altasciences’ integrated full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring and data management, all of which can be customized to meet specific sponsor needs. Altasciences helps sponsors get better drugs to the people who need them faster.